Sepragen to acquire Cytobiologics

By Elaine Rigoli

Tampa, Fla., May 17 - Sepragen Corp. announced the signing of a letter of intent to acquire substantially all of the assets of Cytobiologics, Inc.

The assets include laboratory equipment and intellectual property related to certain rapid assays and a high-density bioreactor, which complements Sepragen's existing high-density bioreactor currently in "alpha development," the company said in a news release.

Located in Hayward, Calif., Sepragen provides bio-purification products that enable biotech companies to develop and produce biopharmaceuticals.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.